Cannabis Law Report

JANUARY 12, 2022

OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. 14, 2021, the sale of Gb Sciences’ Las Vegas cannabis facility was finalized on Dec. Media Contact.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 3, 2021

Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

FloridaMarijuana.net

JUNE 13, 2018

For centuries, humans have relied on the cannabis plant for its therapeutic properties. More than ever, cannabis can aid in the treatment of chronic disease and as a supplement to cancer treatments. Cannabis has given cancer patients relief , improved their mood and anxiety, and relieved insomnia.

Clinical Trials 189

Clinical Trials Marijuana Patients Chronic Pain 189

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

JULY 16, 2020

Despite the novelty of its drug policy findings, the document has gone largely unnoticed by reform advocates and the media. The panel, led by Jake Leinenkugel (a presidential nominee), asserted that psychedelics, such as MDMA and psilocybin, as well as cannabis, present promising ways to treat mental health conditions among military veterans.

Research and Development 95

Research and Development Clinical Trials Treatment Compliance 95

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receiv e gelatin capsules containing THC and CBD daily.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. CannabisFN.com and CFN Media, have been hired to create awareness. Mental Health Challenges. Psychedelics Provide a Solution.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

AUGUST 21, 2019

PUBLISHER: CANNABIS LAW REPORT. Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said the children’s experiences on medicinal cannabis in the should be taken into account as evidence of how well the drug works. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

AUGUST 16, 2021

–(BUSINESS WIRE)–Celebrity blogger and media personality Perez Hilton and leading hemp-based CBD researchers have forged a business partnership in support of My True 10 , a CBD Gummies line available at mytrue10.com Perez Hilton’s Personal Wellness Journey Encourages & Supports Others to Live Well. CARSON CITY, Nev.–(BUSINESS

Food 105

Food CBD Research and Development Clinical Trials 105

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

OCTOBER 5, 2021

Media: media@mymd.com. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

FEBRUARY 10, 2022

A look at key research and clinical trials that were published in 2021, with analysis of themes like microdosing and SSRI interactions. There’s no two ways about it: this is a text-heavy long-read: apologies in advance for those that prefer their media diet to be a little more visual. and Canada. Access the PDF here.

Clinical Trials 52

Clinical Trials Microdosing Pharmaceutical Policy 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Media: Liz Melone. Visit us at www.goldfinchbio.com to learn more.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

DECEMBER 9, 2021

Media Contact: media@mindmed.co. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Investor Contact: ir@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

JUNE 7, 2021

Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. For more information, please contact the Company at: Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

MMJ Recs

DECEMBER 22, 2023

As the United States navigates through a complex web of legal, social, and medical considerations, public opinion on medical cannabis has evolved significantly over the years. The changing public opinion is evident in the increasing number of states legalizing medical cannabis and the growing support for such measures.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Weedistry

JANUARY 28, 2019

Ontario-based Oriol Rhodes has over 30 years of experience in the healthcare industry, but it’s only recently that she has ventured into an uncharted territory: cannabis. “A Can medical cannabis be the solution? The first conversation opened with Chamberland thinking the family would be dead-set against the use of medicinal cannabis.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain Data 40

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Media Releases. Track Inquiry.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. Media Contact: media@mymd.com. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Miss Marijuana

JUNE 30, 2019

I mean duh, with social media, bosses that don’t understand you have a life and the new Bob Dylan documentary on Netflix – how can anyone doze off and dream anymore? RELATED: I’m A Business Owner Who Uses Cannabis & CBD For Anxiety. Did you know sleep deficiency is a pretty common health issue in the United States?

Sleep 72

Sleep CBD Clinical Trials Oil 72

Cannabis Law Report

DECEMBER 9, 2021

MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Media Contact nuelife@derris.com. For more information, please visit www.nue.life. SOURCE Nue Life Health.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JULY 7, 2021

Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. For further information: For media inquiries: Contact Jonathan McGuire, Assistant Vice President, Corporate Communications, Horizons ETFs Management (Canada) Inc.,

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

JANUARY 6, 2022

Scott will work closely with the management team to further develop the company’s internal and external communications with a focus on strategy, branding, social media presence and investor communications.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Media Enquiries: Sam Brown Inc. media enquiries.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Established history of providing ketamine infusion services: The management team at KWC has been in ?

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 11 × 11. 15 × 15.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 8, 2021

cbdMD began its first phase of research in the Fall of 2020, with its first in vivo animal study and clinical trials. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. and are difficult to predict. cbdMD, Inc.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Veriheal

JUNE 24, 2021

The director was spoken to regarding psychedelics and cannabis by Senator Brian Schatz during a Senate Appropriations subcommittee hearing. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

Cannabis Law Report

OCTOBER 5, 2021

The review excludes pre-clinical trials (i.e. You can read our full media release and see the TGA’s full report here >> And read more recent NEWS articles here. experimental pharmacology studies in test tube or animal models).

Treatment 52

Treatment Conditions Medicine Clinical Trials 52